Objective: Transurethral resection of bladder tumour (TURBT) is a common urological procedure. With improvements in technology, technique and community support, our unit was able to implement a dedicated day-case pathway for patients undergoing TURBT. The aim of this study was to prove that this has been a safe and cost-effective improvement to our urology service. Patients and methods: A retrospective audit was carried out of 312 elective TURBT cases performed in one centre between 2011 and 2014 (36 excluded for lack of data/emergency status). Data were gathered regarding length of stay, causes of delayed discharge, readmissions and resection quality. Results: In 2011, 11% of TURBTs were performed as day cases, and 66% had an overnight stay. After introduction of the TURBT pathway, by 2014, 68% patients went home the same day, and 21% had an overnight stay. The 30-day readmission rate in 2011 was 7% (mostly following overnight stays), whereas 6% were readmitted in 2014. Resection quality was comparable across the two groups. Conclusion: Our experience suggests that day-case TURBT can be widely implemented without compromising quality or patient safety. Level of evidence: Not applicable for this multicentre audit.

Bladder cancer is a common genitourinary tract malignancy. Urothelial carcinoma is the most frequent type of bladder cancer and it commonly metastasises to lymph nodes, bone, lung and liver by a haematogenous route. Skeletal metastases are very rare and are usually present in patients with advanced metastatic disease. We present an unusual case of a 71-year-old male with a urothelial carcinoma metastasis to the vastus lateralis muscle 3 months following a cystoprostatectomy for muscle invasive bladder cancer.

Ali Serdar Gözen, et al.; Robot-assisted vasovasostomy and vasoepididymostomy: Current status and review of the literature.